Semaglutide may effect weight loss upto 20% in obese: NEJM Medha Baranwal12 Feb 2021 11:45 AM ISTUK: Once-weekly semaglutide (2.4 mg) in adjunct with diet and exercise, is effective for weight loss in non-diabetic obese or overweight adults, finds...
Semaglutide reduces major adverse CV event risk in Diabetics with raised triglycerides MD Bureau1 Jan 2021 5:15 PM ISTA posthoc analysis on SUSTAIN 6 and PIONEER 6 trial showed semaglutide was associated with consistent reduction in major Adverse cardiovascular event...
Semaglutide to be sold only on prescription of Endocrinologist, PG Medicine in India: CDSCO Committee Farhat Nasim22 Dec 2020 4:58 PM ISTNew Delhi: In a major development, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organisation (CDSCO) has...
Oral semaglutide leads to weight loss by improving eating control in diabetics: Study Medha Baranwal18 Dec 2020 11:15 AM ISTDenmark: Patients with type 2 diabetes (T2D) taking oral semaglutide for 12 weeks had lower energy intake resulting in reduced body fat mass,...
Semaglutide shows promise in patients with nonalcoholic steatohepatitis: NEJM Dr Satabdi Saha18 Nov 2020 6:00 PM ISTAccording to the findings of a recently published study in New England Journal of Medicine, treatment with semaglutide resulted in a significantly...
Semaglutide tied to significant weight loss when added to intensive behavioral therapy Hina Zahid10 Nov 2020 2:45 PM ISTPLAINSBORO, N.J. -Researchers have found in a new phase 3a trial that Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo...
Semaglutide effectively manages blood sugar and kidney function in diabetes: Lancet Dr Satabdi Saha28 Sept 2020 12:00 PM ISTPatients with type 2 diabetes have increased risk of developing chronic kidney disease. Researchers conducted a study to examine the effects of...
Type 2 diabetes: Semaglutide significantly reduces blood sugar and body weight Medha Baranwal16 July 2020 11:00 AM ISTCanada: Initiation of semaglutide therapy in type 2 diabetes (T2D) patients naive to GLP-1 RA therapy helped in a significant reduction of...
FDA approves injection semaglutide for reducing major adverse CV events in patients with diabetes and known heart disease Medha Baranwal17 Jan 2020 10:22 AM ISTUSA: Semaglutide (Ozempic) injection 0.5 mg or 1 mg has received the US Food and Drug Administration (FDA) approval for the reduction of major adverse...
